Creative Bioarray
  • USA:
  • Europe:
LOGO
  • Home
    • About Us
    • Contact Us
    • Events
  • Screening
    • Ionic Screening Service
      • Ion Flux Assay
      • Fluorescence Assay
      • Patch-clamp Assay
    • Ionic Screening Panel
      • Sodium Channels
      • Potassium Channels
      • Chloride Channels
      • Calcium Channels
      • TRP Channels
      • ATP gated P2X Channels
      • ASICs
      • Nicotinic Acetylcholine Receptors
      • Ionotropic Glutamate-gated Receptors
      • GABAa Receptors
      • Glycine Receptors
      • 5-HT Receptors3
      • Cystic Fibrosis Transmembrane Conductance Regulators (CFTR)
      • Other Ion Channels
    • Stable Cell Lines
      • Ion Channel Expressing Cell
      • GPCR Expressing Cell
      • Other Membrane Receptors/Transporters/Exchangers Expression Cell
      • Customized Ionic Channel Expression System
  • Cardiology
    • Cardiac Ion Channel Screen Panels
      • HERG (IKR, KV11.1)
      • Cav1.2
      • Kv4.3
      • KCNQ1/mink/Kv7.1
      • Kir2.1
      • Nav1.5
      • Kv1.5
      • HCN1&HCN4
      • Other Ion Channels
    • CiPA
      • CiPA Cardiac Channel Assays
      • CiPA In silico Modeling
      • CiPA Translational Assays
    • 3D Cardiotoxicity
    • Cardiomyocyte Functions
      • Action Potential Properties
      • Calcium Transient in Cardiomyocytes
      • QT Service Using Langendorff Perfused Heart
    • Cardiac in vivo Assays
      • QRS, QT Waves Detection by ECG
  • Neurology
    • Neurotransmission Functions
      • sEPSC/sIPSC Recordings
      • fEPSP / Populational Spikes Recordings
      • LTP & LTD Formation or Deficit Detection
    • Basic Neuronal Activity
      • Action Potential Properties Assay
      • NMDA/AMPA Ratio Test
      • Calcium Signaling Test
      • Customized Electrophysiological Test
    • Neuronal in vivo Assays
      • In vivo Extra-cellular Recordings/Whole-cell Patch-clamp Recordings
      • Continuous Telemetric EEG Recordings
    • Animal Behavior Tests
      • Spontaneous Locomotor Functions
      • Cognitive Functions
      • Anxiety-Depression and Social Interaction Evaluation
      • Assays for Neuropsychiatric Disorders
  • Ophthalmology
  • Platform
    • Experiment Systems
      • Xenopus Oocyte Screening Model
      • Acute Isolated Cardiomyocytes
      • Acute Dissociated Neurons
      • Primary Cultured Neurons
      • Cultured Neuronal Cell Lines
      • iPSC-derived Cardiomyocytes/Neurons
      • Acute/Cultured Organotypic Brain Slices
      • Oxygen Glucose Deprivation Model
      • 3D Cell Culture
      • iPSC-derived Neurons
      • Isolation and culture of neural stem/progenitor cells
    • Animal Models
      • Alzheimer's Disease Model
      • Parkinson's Disease Model
      • Huntington's Disease Model
      • Epilepsy Model
      • ALS Model
      • Psychiatric Model
      • Autism Spectrum Disorder
      • Cerebral-Spinal Injury Model
      • Pain Model
      • Stroke Model
      • Fragile X Model
      • Acute/Chronic Heart Failure Model
    • Techinques
      • Manual Patch-clamp Technique
      • Automated Patch-clamp
      • Multi-Electrode Array (MEA)
      • FluxORâ„¢ Thallium Assay
      • FLIPR Detection System
      • Optogenetics
      • Neuronal Tract Tracing
    • Resource
      • Technical Methods
      • Neuroscience
      • Channelopathies
      • Channelomics
    • Equipment
  • Order
  • Careers
  • Home
  • Platform
  • Resource
  • Channelopathies
  • Screening
  • Ionic Screening Service Ionic Screening Panel Stable Cell Lines
  • Cardiology
  • CiPA 3D Cardiotoxicity Cardiomyocyte Functions Cardiac in vivo Assays Cardiac Ion Channel Screen Panels
  • Neurology
  • Basic Neuronal Activity Neurotransmission Functions Neuronal in vivo Assays Animal Behavior Tests
  • Platform
  • Experiment Systems Animal Models Techinques Resource Equipment

Spinocerebellar Ataxia Type-13

Spinocerebellar ataxia 13 (SCA13) is a rare subtype of spinocerebellar ataxia (SCA), a group of neurological diseases that cause degeneration of the brain and spinal cord. The age of symptoms and the type and severity of SCA13 symptoms are heterogeneous, and they may vary from person to person even in the same family. In almost every case, the disease progresses very slowly and does not affect a person's lifespan. Symptoms are most common in early childhood or late middle age, but may persist from infancy to 60 years of age. Childhood forms are usually not obvious, but they may also include mild to moderate learning problems, which take longer to learn to crawl, walk or run (slow motor skills development), or have seizures.

The main symptoms of SCA13 include difficulty coordinating movement (ataxia), especially walking; abnormal eye movements (nystagmus); mild to moderate intellectual disability; and involuntary muscle twitches (myoclonic twitches). Other symptoms may include speech difficulties (dysarthria), eating difficulties (dysphagia), slow movements (slow movement), mild bladder problems, stiffness and brisk deep tendon reflexes, and loss of vibration sensation.

SCA13 is caused by changes or mutations in the KCNC3 gene, which encodes a voltage-gated potassium channel K V3.3 and is inherited in an autosomal dominant manner. Unlike many other types of SCA, SCA13 is not caused by repeated polyglutamine amplification, but a point mutation. There are two known mutations in this gene that cause SCA13: The first mutation, R420H, is located in the S4 segment of the voltage sensing channel. Since this mutation neutralizes a site that is important for voltage sensing, it causes channel barriers. Neurons expressing such channels cannot transmit information in time with sufficient fidelity. The second mutation F448L associated with SCA13 caused changes in functional channel dynamics. Compared with the wild-type, the half activation voltage of these channels shifted by 13mV hyperpolarization. Compared with the wild type, the inactivation of these channels is also greatly slowed down. This leads to a longer time after neuron hyperpolarization, so the maximum firing rate is reduced.The former mutation that affects channel gating characteristics and neuronal excitability is related to the early-onset phenotypes, while the latter mutation that affects the current amplitude is related to the late-onset phenotypes.

Spinocerebellar Ataxia Type-13

Figure 1. Kv3.3 potassium channels and spinocerebellar ataxia. ()

Like some other SCA subtypes, this gene is abundantly expressed in Purkinje cells and is believed to play an important role in promoting high-frequency action potential firing. Since the symptoms of SCA13 may be similar to other types of SCA, genetic testing can be used to confirm the diagnosis. In addition, compared with most other SCAs, brain MRI detection will find the part of the brain that helps control movement (cerebellum) loses brain cells (neurons), but the brain stem or part of the brain has no obvious brain for higher thinking (cerebral cortex) Cell loss. Treatment may include anti-epileptics, special assistance in school, speech therapy and communication equipment, and/or assistance such as crutches and walkers in the later stages of the disease. Maintaining a healthy weight can help people walk longer without help. The use of alcohol may increase the severity of uncoordinated exercise (ataxia).

References

  1. Ataxia espinocerebelosa tipo 13. Orphanet. 2017; http://www.orpha.net/consor/cgi-bin/OC_Exp.php?Expert=98768&lng=ES.
  2. Subramony S, et al.; Comprehensive Phenotype of the p.Arg420his Allelic Form of Spinocerebellar Ataxia Type 13. 2013, 12(3):932-936.
  3. Stefan-M Pulst. Spinocerebellar Ataxia Type 13. GeneReviews. 2012, http://www.ncbi.nlm.nih.gov/books/NBK1225/.
  4. Yalan Zhang, et al.; Kv3.3 potassium channels and spinocerebellar ataxia. J Physiol. 2016, 594.16 pp 4677-4684.
For research use only.

Related Section

  • Technical Methods
  • Neuroscience
  • Channelomics

Inquiry


Subscribe
  • Links
  • Sodium Channels
  • Calcium Channels
  • Potassium Channels
  • Chloride Channels
  • TRP Channels
  • ATP gated P2X Channels
  • ASICs
  • USA
  • Europe

Copyright © 2025 Creative Bioarray. All rights reserved.